Recent studies have suggested the KOR involvement in diverse neuropsychiatric or neurological disorders, e.g., epilepsy, addictions, alcohol abuse, depression, schizophrenia and anxiety, therefore the development of novel, efficient KOR antagonist with high selectivity and medication-like profile attracted the medicinal chemists’ interest [153,154,155]. The gene discussed is OPRK1; the disease is depressive symptom measurement.